LONDON (Alliance News) - Pharmaceutical firm Futura Medical PLC said Wednesday it has enrolled its first patient on a late-stage clinical trial of its MED2002 erectile dysfunction treatment.
MED2002 is a topical glyceryl trinitrate gel used for the treatment of erectile dysfunction. The FM57 clinical trial has begun its phase three study with the enrolment of its first patient. The phase three trial remains on track with headline data expected by the end of 2019.
"We are pleased to announce the first patient enrolment in our first European phase three trial with MED2002," Futura Chief Executive Officer James Barder said. "This is an important milestone for Futura, building on the success of both the phase two and PK [pharmacokinetics] data."
"Futura is now in a position to build value by progressing the development of MED2002 through its planned phase three studies, and we are excited to be moving closer to bringing an innovative, highly differentiated ED product to market that could help the many ED patients whose needs are not met by current treatments", Barder explained.
Shares in Futura were 0.2% lower at 7.54 pence on Wednesday.